1
|
Encerrado-Manriquez AM, Pouv AK, Fine JD, Nicklisch SCT. Enhancing knowledge of chemical exposures and fate in honey bee hives: Insights from colony structure and interactions. THE SCIENCE OF THE TOTAL ENVIRONMENT 2024; 916:170193. [PMID: 38278225 DOI: 10.1016/j.scitotenv.2024.170193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 01/13/2024] [Accepted: 01/13/2024] [Indexed: 01/28/2024]
Abstract
Honey bees are unintentionally exposed to a wide range of chemicals through various routes in their natural environment, yet research on the cumulative effects of multi-chemical and sublethal exposures on important caste members, including the queen bee and brood, is still in its infancy. The hive's social structure and food-sharing (trophallaxis) practices are important aspects to consider when identifying primary and secondary exposure pathways for residential hive members and possible chemical reservoirs within the colony. Secondary exposures may also occur through chemical transfer (maternal offloading) to the brood and by contact through possible chemical diffusion from wax cells to all hive members. The lack of research on peer-to-peer exposures to contaminants and their metabolites may be in part due to the limitations in sensitive analytical techniques for monitoring chemical fate and dispersion. Combined application of automated honey bee monitoring and modern chemical trace analysis techniques could offer rapid progress in quantifying chemical transfer and accumulation within the hive environment and developing effective mitigation strategies for toxic chemical co-exposures. To enhance the understanding of chemical fate and toxicity within the entire colony, it is crucial to consider both the intricate interactions among hive members and the potential synergistic effects arising from combinations of chemical and their metabolites.
Collapse
Affiliation(s)
| | - Amara K Pouv
- Department of Environmental Toxicology, University of California-Davis, Davis, CA 95616, USA; Department of Fisheries, Animal, and Veterinary Science, University of Rhode Island, Kingston, RI 02881, USA
| | - Julia D Fine
- Invasive Species and Pollinator Health Research Unit, USDA-ARS, 3026 Bee Biology Rd., Davis, CA 95616, USA
| | - Sascha C T Nicklisch
- Department of Environmental Toxicology, University of California-Davis, Davis, CA 95616, USA.
| |
Collapse
|
2
|
Maier MLV, Siddens LK, Pennington JM, Uesugi SL, Labut EM, Vertel EA, Anderson KA, Tidwell LG, Tilton SC, Ognibene TJ, Turteltaub KW, Smith JN, Williams DE. Impact of phenanthrene co-administration on the toxicokinetics of benzo[a]pyrene in humans. UPLC-accelerator mass spectrometry following oral microdosing. Chem Biol Interact 2023; 382:110608. [PMID: 37369263 PMCID: PMC10782561 DOI: 10.1016/j.cbi.2023.110608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 06/13/2023] [Accepted: 06/16/2023] [Indexed: 06/29/2023]
Abstract
Current risk assessments for environmental carcinogens rely on animal studies utilizing doses orders of magnitude higher than actual human exposures. Epidemiological studies of people with high exposures (e.g., occupational) are of value, but rely on uncertain exposure data. In addition, exposures are typically not to a single chemical but to mixtures, such as polycyclic aromatic hydrocarbons (PAHs). The extremely high sensitivity of accelerator mass spectrometry (AMS) allows for dosing humans with known carcinogens with de minimus risk. In this study UPLC-AMS was used to assess the toxicokinetics of [14C]-benzo[a]pyrene ([14C]-BaP) when dosed alone or in a binary mixture with phenanthrene (Phe). Plasma was collected for 48 h following a dose of [14C]-BaP (50 ng, 5.4 nCi) or the same dose of [14C]-BaP plus Phe (1250 ng). Following the binary mixture, Cmax of [14C]-BaP significantly decreased (4.4-fold) whereas the volume of distribution (Vd) increased (2-fold). Further, the toxicokinetics of twelve [14C]-BaP metabolites provided evidence of little change in the metabolite profile of [14C]-BaP and the pattern was overall reduction consistent with reduced absorption (decrease in Cmax). Although Phe was shown to be a competitive inhibitor of the major hepatic cytochrome P-450 (CYP) responsible for metabolism of [14C]-BaP, CYP1A2, the high inhibition constant (Ki) and lack of any increase in unmetabolized [14C]-BaP in plasma makes this mechanism unlikely to be responsible. Rather, co-administration of Phe reduces the absorption of [14C]-BaP through a mechanism yet to be determined. This is the first study to provide evidence that, at actual environmental levels of exposure, the toxicokinetics of [14C]-BaP in humans is markedly altered by the presence of a second PAH, Phe, a common component of environmental PAH mixtures.
Collapse
Affiliation(s)
- Monica L Vermillion Maier
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA.
| | - Lisbeth K Siddens
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA.
| | - Jamie M Pennington
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA.
| | - Sandra L Uesugi
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA.
| | - Edwin M Labut
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA.
| | - Emily A Vertel
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA.
| | - Kim A Anderson
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, 97331, USA.
| | - Lane G Tidwell
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA.
| | - Susan C Tilton
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, 97331, USA.
| | - Ted J Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, 94550, USA.
| | - Kenneth W Turteltaub
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, 94550, USA; Biology and Biotechnology Research Division, Lawrence Livermore National Laboratory, Livermore, CA, 94550, USA.
| | - Jordan N Smith
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, 97331, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, 99354, USA.
| | - David E Williams
- Linus Pauling Institute, Oregon State University, Corvallis, OR, 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, 97331, USA
| |
Collapse
|
3
|
Vermillion Maier ML, Siddens LK, Pennington JM, Uesugi SL, Tilton SC, Vertel EA, Anderson KA, Tidwell LG, Ognibene TJ, Turteltaub KW, Smith JN, Williams DE. Benzo[a]pyrene toxicokinetics in humans following dietary supplementation with 3,3'-diindolylmethane (DIM) or Brussels sprouts. Toxicol Appl Pharmacol 2023; 460:116377. [PMID: 36642108 PMCID: PMC9946811 DOI: 10.1016/j.taap.2023.116377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 01/05/2023] [Accepted: 01/09/2023] [Indexed: 01/15/2023]
Abstract
Utilizing the atto-zeptomole sensitivity of UPLC-accelerator mass spectrometry (UPLC-AMS), we previously demonstrated significant first-pass metabolism following escalating (25-250 ng) oral micro-dosing in humans of [14C]-benzo[a]pyrene ([14C]-BaP). The present study examines the potential for supplementation with Brussels sprouts (BS) or 3,3'-diindolylmethane (DIM) to alter plasma levels of [14C]-BaP and metabolites over a 48-h period following micro-dosing with 50 ng (5.4 nCi) [14C]-BaP. Volunteers were dosed with [14C]-BaP following fourteen days on a cruciferous vegetable restricted diet, or the same diet supplemented for seven days with 50 g of BS or 300 mg of BR-DIM® prior to dosing. BS or DIM reduced total [14C] recovered from plasma by 56-67% relative to non-intervention. Dietary supplementation with DIM markedly increased Tmax and reduced Cmax for [14C]-BaP indicative of slower absorption. Both dietary treatments significantly reduced Cmax values of four downstream BaP metabolites, consistent with delaying BaP absorption. Dietary treatments also appeared to reduce the T1/2 and the plasma AUC(0,∞) for Unknown Metabolite C, indicating some effect in accelerating clearance of this metabolite. Toxicokinetic constants for other metabolites followed the pattern for [14C]-BaP (metabolite profiles remained relatively consistent) and non-compartmental analysis did not indicate other significant alterations. Significant amounts of metabolites in plasma were at the bay region of [14C]-BaP irrespective of treatment. Although the number of subjects and large interindividual variation are limitations of this study, it represents the first human trial showing dietary intervention altering toxicokinetics of a defined dose of a known human carcinogen.
Collapse
Affiliation(s)
- Monica L Vermillion Maier
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, ALS 1007, Oregon State University, Corvallis, OR 97331, USA.
| | - Lisbeth K Siddens
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Jamie M Pennington
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Sandra L Uesugi
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA.
| | - Susan C Tilton
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA.
| | - Emily A Vertel
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Kim A Anderson
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA.
| | - Lane G Tidwell
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA.
| | - Ted J Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
| | - Kenneth W Turteltaub
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA; Biology and Biotechnology Research Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
| | - Jordan N Smith
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
| | - David E Williams
- Linus Pauling Institute, Oregon State University, Corvallis, OR 97331, USA; Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR 97331, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR 97331, USA.
| |
Collapse
|
4
|
Baliu-Rodriguez D, Stewart BJ, Ognibene TJ. HPLC-Parallel accelerator and molecular mass spectrometry analysis of 14C-labeled amino acids. J Chromatogr B Analyt Technol Biomed Life Sci 2023; 1216:123590. [PMID: 36669256 PMCID: PMC9994536 DOI: 10.1016/j.jchromb.2022.123590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2022] [Accepted: 12/31/2022] [Indexed: 01/06/2023]
Abstract
Accelerator mass spectrometry (AMS) is the method of choice for quantitation of low amounts of 14C-labeled biomolecules. Despite exquisite sensitivity, an important limitation of AMS is its inability to provide structural information about the analyte. This limitation is not critical when the labeled compounds are well-characterized prior to AMS analysis. However, analyte identity is important in other experiments where, for example, a compound is metabolized and the structures of its metabolites are not known. We previously described a moving wire interface that enables direct AMS measurement of liquid sample in the form of discrete drops or HPLC eluent without the need for individual fraction collection, termed liquid sample-AMS (LS-AMS). We now report the coupling of LS-AMS with a molecular mass spectrometer, providing parallel accelerator and molecular mass spectrometry (PAMMS) detection of analytes separated by liquid chromatography. The repeatability of the method was examined by performing repeated injections of 14C-labeled tryptophan, and relative standard deviations of the 14C peak areas were ≤10.57% after applying a normalization factor based on a standard. Five 14C-labeled amino acids were separated and detected to provide simultaneous quantitative AMS and structural MS data, and AMS results were compared with solid sample-AMS (SS-AMS) data using Bland-Altman plots. To demonstrate the utility of the workflow, yeast cells were grown in a medium with 14C-labeled tryptophan. The cell extracts were analyzed by PAMMS, and 14C was detected in tryptophan and its metabolite kynurenine.
Collapse
Affiliation(s)
- David Baliu-Rodriguez
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94551, USA.
| | - Benjamin J Stewart
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| | - Ted J Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA 94551, USA
| |
Collapse
|
5
|
Babin V, Taran F, Audisio D. Late-Stage Carbon-14 Labeling and Isotope Exchange: Emerging Opportunities and Future Challenges. JACS AU 2022; 2:1234-1251. [PMID: 35783167 PMCID: PMC9241029 DOI: 10.1021/jacsau.2c00030] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 03/01/2022] [Accepted: 03/02/2022] [Indexed: 05/04/2023]
Abstract
Carbon-14 (14C) is a gold standard technology routinely utilized in pharmaceutical and agrochemical industries for tracking synthetic organic molecules and providing their metabolic and safety profiles. While the state of the art has been dominated for decades by traditional multistep synthetic approaches, the recent emergence of late-stage carbon isotope labeling has provided new avenues to rapidly access carbon-14-labeled biologically relevant compounds. In particular, the development of carbon isotope exchange has represented a fundamental paradigm change, opening the way to unexplored synthetic transformations. In this Perspective, we discuss the recent developments in the field with a critical assessment of the literature. We subsequently discuss research directions and future challenges within this rapidly evolving field.
Collapse
|
6
|
Dell'isola A, Brown RT, Jones S, Kitson SL, Moody TS, Syvret J, Upeandran B, Watters WH. Synthesis of carbon-14-labelled peptides. J Labelled Comp Radiopharm 2019; 62:713-717. [PMID: 31211429 DOI: 10.1002/jlcr.3777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 06/03/2019] [Accepted: 06/03/2019] [Indexed: 11/06/2022]
Abstract
Carbon-14 (14 C)-labelled active pharmaceutical ingredients (APIs) and investigational medicinal products (IMPs) are required for phase 0/I to phase III mass balance and micro-dosing clinical trials. In some cases, this may involve the synthesis of 14 C-labelled peptides, and the analysis can be performed by accelerated mass spectrometry (AMS). The 14 C-peptide is typically prepared by the solid-phase peptide synthesis (SPPS) approach using custom-made glassware for the key coupling steps. Further modification of the purified 14 C-peptide can then be performed.
Collapse
Affiliation(s)
- Antonio Dell'isola
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| | - Rodney T Brown
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| | - Stuart Jones
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| | - Sean L Kitson
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| | - Thomas S Moody
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| | - Jason Syvret
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| | | | - William H Watters
- Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon, UK
| |
Collapse
|
7
|
Kingston C, Wallace MA, Allentoff AJ, deGruyter JN, Chen JS, Gong SX, Bonacorsi S, Baran PS. Direct Carbon Isotope Exchange through Decarboxylative Carboxylation. J Am Chem Soc 2019; 141:774-779. [PMID: 30605319 DOI: 10.1021/jacs.8b12035] [Citation(s) in RCA: 54] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
A two-step degradation-reconstruction approach to the carbon-14 radiolabeling of alkyl carboxylic acids is presented. Simple activation via redox-active ester formation was followed by nickel-mediated decarboxylative carboxylation to afford a range of complex compounds with ample isotopic incorporations for drug metabolism and pharmacokinetic studies. The practicality and operational simplicity of the protocol were demonstrated by its use in an industrial carbon-14 radiolabeling setting.
Collapse
Affiliation(s)
- Cian Kingston
- Department of Chemistry , The Scripps Research Institute , 10550 North Torrey Pines Road , La Jolla , California 92037 , United States
| | - Michael A Wallace
- Radiochemistry , Bristol-Myers Squibb Company , P.O. Box 4000, Princeton , New Jersey 08543 , United States
| | - Alban J Allentoff
- Radiochemistry , Bristol-Myers Squibb Company , P.O. Box 4000, Princeton , New Jersey 08543 , United States
| | - Justine N deGruyter
- Department of Chemistry , The Scripps Research Institute , 10550 North Torrey Pines Road , La Jolla , California 92037 , United States
| | - Jason S Chen
- Automated Synthesis Facility , The Scripps Research Institute , 10550 North Torrey Pines Road , La Jolla , California 92037 , United States
| | - Sharon X Gong
- Radiochemistry , Bristol-Myers Squibb Company , P.O. Box 4000, Princeton , New Jersey 08543 , United States
| | - Samuel Bonacorsi
- Radiochemistry , Bristol-Myers Squibb Company , P.O. Box 4000, Princeton , New Jersey 08543 , United States
| | - Phil S Baran
- Department of Chemistry , The Scripps Research Institute , 10550 North Torrey Pines Road , La Jolla , California 92037 , United States
| |
Collapse
|
8
|
Madeen E, Siddens LK, Uesugi S, McQuistan T, Corley RA, Smith J, Waters KM, Tilton SC, Anderson KA, Ognibene T, Turteltaub K, Williams DE. Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing. Toxicol Appl Pharmacol 2018; 364:97-105. [PMID: 30582946 DOI: 10.1016/j.taap.2018.12.010] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Revised: 12/13/2018] [Accepted: 12/17/2018] [Indexed: 10/27/2022]
Abstract
Benzo[a]pyrene (BaP), is a known human carcinogen (International Agency for Research on Cancer (IARC) class 1). The remarkable sensitivity (zepto-attomole 14C in biological samples) of accelerator mass spectrometry (AMS) makes possible, with de minimus risk, pharmacokinetic (PK) analysis following [14C]-BaP micro-dosing of humans. A 46 ng (5 nCi) dose was given thrice to 5 volunteers with minimum 2 weeks between dosing and plasma collected over 72 h. [14C]-BaPeq PK analysis gave plasma Tmax and Cmax values of 1.25 h and 29-82 fg/mL, respectively. PK parameters were assessed by non- compartment and compartment models. Intervals between dosing ranged from 20 to 420 days and had little impact on intra-individual variation. DNA, extracted from peripheral blood mononuclear cells (PBMCs) of 4 volunteers, showed measurable levels (LOD ~ 0.5 adducts/1011 nucleotides) in two individuals 2-3 h post-dose, approximately three orders of magnitude lower than smokers or occupationally-exposed individuals. Little or no DNA binding was detectable at 48-72 h. In volunteers the allelic variants CYP1B1*1/*⁎1, *1/*3 or *3/*3 and GSTM1*0/0 or *1 had no impact on [14C]-BaPeq PK or DNA adduction with this very limited sample. Plasma metabolites over 72 h from two individuals (one CYP1B1*1/*1 and one CYP1B1*3/*3) were analyzed by UPLC-AMS. In both individuals, parent [14C]-BaP was a minor constituent even at the earliest time points and metabolite profiles markedly distinct. AMS, coupled with UPLC, could be used in humans to enhance the accuracy of pharmacokinetics, toxicokinetics and risk assessment of environmental carcinogens.
Collapse
Affiliation(s)
- Erin Madeen
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA
| | - Lisbeth K Siddens
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| | - Sandra Uesugi
- Linus Pauling Institute, Oregon State University, Corvallis, OR, USA
| | | | - Richard A Corley
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
| | - Jordan Smith
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
| | - Katrina M Waters
- NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Chemical Biology and Exposure Science, Pacific Northwest National Laboratory, Richland, WA, USA
| | - Susan C Tilton
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA
| | - Kim A Anderson
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA
| | - Ted Ognibene
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, USA
| | - Kenneth Turteltaub
- Center for Accelerator Mass Spectrometry, Lawrence Livermore National Laboratory, Livermore, CA, USA; Biology and Biotechnology Research Division, Lawrence Livermore National Laboratory, Livermore, CA, USA
| | - David E Williams
- Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; NIEHS Superfund Research Program, Oregon State University, Corvallis, OR, USA; Linus Pauling Institute, Oregon State University, Corvallis, OR, USA.
| |
Collapse
|
9
|
Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies. PLoS One 2018; 13:e0205435. [PMID: 30332475 PMCID: PMC6192596 DOI: 10.1371/journal.pone.0205435] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Accepted: 09/25/2018] [Indexed: 12/13/2022] Open
Abstract
New therapeutic biological entities such as bispecific antibodies targeting tissue or specific cell populations form an increasingly important part of the drug development portfolio. However, these biopharmaceutical agents bear the risk of extensive target-mediated drug disposition or atypical pharmacokinetic properties as compared to canonical antibodies. Pharmacokinetics and bio-distribution studies become therefore more and more important during lead optimization. Biologics present, however, greater analytical challenges than small molecule drugs due to the mass and selectivity limitation of mass spectrometry and ligand-binding assay, respectively. Radiocarbon (14C) and its detection methods, such as the emerging 14C cavity ring down spectroscopy (CRDS), thus can play an important role in the large molecule quantitation where a 14C-tag is covalently bound through a stable linker. CRDS has the advantage of a simplified sample preparation and introduction system as compared to accelerator mass spectrometry (AMS) and can be accommodated within an ordinary research laboratory. In this study, we report on the labeling of an anti-IL17 IgG1 model antibody with 14C propionate tag and its detection by CRDS using it as nanotracer (2.1 nCi or 77.7 Bq blended with the therapeutic dose) in a pharmacokinetics study in a preclinical species. We compare these data to data generated by AMS in parallel processed samples. The derived concentration time profiles for anti-IL17 by CRDS were in concordance with the ones derived by AMS and γ-counting of an 125I-labeled anti-IL17 radiotracer and were well described by a 2-compartment population pharmacokinetic model. In addition, antibody tissue distribution coefficients for anti-IL17 were determined by CRDS, which proved to be a direct and sensitive measurement of the extravascular tissue concentration of the antibody when tissue perfusion was applied. Thus, this proof-of-concept study demonstrates that trace 14C-radiolabels and CRDS are an ultrasensitive approach in (pre)clinical pharmacokinetics and bio-distribution studies of new therapeutic entities.
Collapse
|
10
|
Isin EM, Turesky RJ. Introduction: Mass Spectrometry and Emerging Technologies for Biomarker Discovery in the Assessment of Human Health and Disease. Chem Res Toxicol 2016; 29:1901-1902. [PMID: 27989143 DOI: 10.1021/acs.chemrestox.6b00429] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Emre M Isin
- Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development Biotech Unit, AstraZeneca , Pepparedsleden 1, Mölndal SE-431 83, Sweden
| | - Robert J Turesky
- Masonic Cancer Center and Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota , Minneapolis, Minnesota 55455, United States
| |
Collapse
|